Regulatory Actions for April 16, 2026
BioWorld’s April 16, 2026 regulatory snapshot lists a flurry of biopharma and med‑tech actions, ranging from new drug submissions to market approvals and designations. Companies such as Airs, Aligos, AOP, Arbutus, Cala, Dogwood, Immutep, Leadiant, Northstar, Opna, Reach Surgical, Waters and Xspray feature in the roundup. The announcements span U.S., European and Asian regulators, reflecting a globally coordinated pipeline. Collectively, the moves signal robust development activity across oncology, rare diseases and digital‑health platforms.
In the Clinic for April 14, 2026
The "In the clinic for April 14, 2026" page serves as a centralized hub that aggregates the latest Bioworld data snapshots, special reports, and infographics across biopharma, medical technology, and emerging therapeutic areas. It links to analyses on mRNA vaccine...
Stryker Agrees to Buy Amplitude Vascular Systems for IVL Tech
Stryker announced a definitive agreement to acquire Amplitude Vascular Systems, a specialist in intravascular lithotripsy (IVL) technology, for roughly $1.5 billion in cash. The deal broadens Stryker’s cardiovascular portfolio by adding a catheter platform designed for treating heavily calcified coronary lesions,...
CMS Looks to Bring Rx Prior Authorization Into Digital Age
The Centers for Medicare & Medicaid Services (CMS) announced a push to digitize prescription‑drug prior authorization (PA) through electronic prior authorization (ePA) standards. The initiative mandates health plans and pharmacies to adopt interoperable, real‑time PA workflows by the end of...
Appointments and Advancements for April 13, 2026
On April 13, 2026 three biotech firms filed patents on novel drug candidates. Accure Therapeutics disclosed oligopeptide derivatives that inhibit matrix metalloproteinases MMP‑2 and MMP‑9, enzymes linked to cancer invasion and fibrosis. Merck Sharp & Dohme (MSD) introduced indazole‑based blockers of HCN1/2...
Appointments and Advancements for April 10, 2026
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 blockers that alleviate inflammatory and neuropathic pain in rodents without notable cardiovascular effects. Parallel research reveals chronic inflammation in the bone‑marrow niche drives hematopoietic stem cells toward pre‑leukemic clones via cytokines such...
Other News to Note for April 10, 2026
BioWorld’s April 10 briefing highlights three notable developments. Jiangsu and Shanghai Hengrui have patented novel Nav1.8 sodium‑channel blockers, a class of compounds with potential for pain and inflammatory disease therapies. New hematopoietic stem‑cell research links chronic inflammation to early‑stage leukemia, deepening...
Regulatory Actions for April 9, 2026
On April 9, 2026 regulators issued a batch of approvals and designations across biopharma and medical‑technology firms. Anumana secured FDA clearance for its AI‑driven diagnostic platform, while Bausch + Lomb obtained EU approval for a new ocular therapy. Becton Dickinson earned a CE mark for...
VC Activity Drives March Med-Tech Financings to $2.4B
In March, the med‑tech sector highlighted three breakthrough programs that attracted venture capital attention. Jiangsu and Shanghai Hengrui patented selective Nav1.8 sodium‑channel blockers and plan IND‑enabling toxicology this year, targeting chronic pain with a Phase I start in 2027. New single‑cell...
Appointments and Advancements for April 7, 2026
On April 7, 2026, BioWorld reported three notable biotech developments. Jiangsu and Shanghai Hengrui patented novel Nav1.8 sodium‑channel blockers, a potential new class for chronic pain management. Researchers highlighted hematopoietic stem‑cell studies that implicate inflammation as an early driver of...
Kennedy Sidestepping Court Order Sidelining ACIP?
BioWorld’s April 7 briefing highlights three notable developments: Jiangsu and Shanghai Hengrui have patented a new class of Nav1.8 sodium‑channel blockers aimed at chronic pain treatment; recent hematopoietic stem‑cell research underscores inflammation’s role in initiating leukemia; and Infinimmune presented preclinical data...
South Korea Streamlines Biosimilar Review, Clinical Trials
BioWorld Asia’s April 7 2026 briefing highlighted three emerging biotech developments. Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that deliver strong analgesic effects with minimal off‑target activity, positioning them as potential first‑in‑class chronic pain therapies. New research linked chronic inflammation in...
Other News to Note for April 7, 2026
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented novel Nav1.8 sodium‑channel blockers that selectively target pain signaling, showing strong pre‑clinical analgesic activity with minimal off‑target effects. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, creating a microenvironment that...
In the Clinic for April 7, 2026
BioWorld’s April 7, 2026 clinic roundup compiles a broad set of data snapshots, special reports and infographics spanning biopharma, medical technology, and emerging therapeutic areas. The collection links to analyses on M&A activity, GLP‑1 developments in China, mRNA vaccine research, pulsed‑field ablation...
Best of BioWorld: Q1
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that show potent analgesic activity with minimal off‑target effects, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes hematopoietic stem cells, fostering early...
